Stem Cells: An Alternative Therapy for COVID-19 and Cytokine Storm provides mechanistic insights into the role of stem cells to combat COVID-19 outbreak and other pathologies where cytokines storm is the cause of concern for e.g., radiation exposure, multiple organ failure and sepsis. There has been an increase in number of cases of new diseases in the last decade, including mucormycosis, Zika virus, H1N1 influenza virus, among others. These diseases can be characterized by the induction of cytokine storm, which is mainly responsible for morbidity and mortality.
Stem cell therapy has emerged as a potential treatment for viral diseases, including, but not limited to, COVID-19. Interestingly, clinical trials in patients with COVID-19 complications depicted faster recovery in patients post mesenchymal stem cells therapy owing to the decreased cytokines levels, anti-viral effects and regeneration of the infected tissue.
1. Introduction - p. xxiii 2. Part 1: Outbreak of novel disease - p. xxiv 3. Chapter 1. Targets of SARS-CoV-2: therapeutic implications for COVID-19 - p. 3 4. Part 2: COVID-19 Biology - p. 10 5. Chapter 2. COVID-19 biology: cytokine storms and their implications - p. 17 6. Part 3: SARS-CoV-2 associated complications - p. 25 7. Chapter 3. Comparative clinical investigation of blood profiling in COVID-19 patients - p. 29 8. Chapter 4. SARS-CoV-2-associated complications - p. 45 9. Part 4: Current therapeutics available against SARS-CoV-2 - p. 51 10. Chapter 5. COVID-19 diagnostic approaches and modern mesenchymal stem cell-based treatment - p. 57 11. Chapter 6. Modulation of pentose phosphate pathway augments the efficacy of 2-deoxy-D-glucose in COVID-19 management - p. 69 12. Chapter 7. Therapeutic landscape of SARS-CoV-2 - p. 83 13. Chapter 8. Pharmacotherapeutics for cytokine storm in COVID-19 - p. 101 14. Chapter 9. Clinical investigation of COVID-19 prevention and treatment - p. 127 15. Chapter 10. Potential therapeutic landscape of COVID-19: molecular targets, repurposed drugs, and nano- and cell-based intervention - p. 139 16. Chapter 11. Medical care for SARS-CoV-2 - p. 159 17. Part 5: Opportunistic infections and complications post-COVID-19 - p. 170 18. Chapter 12. Therapeutic approaches for opportunistic infection post-COVID-19 pandemic - p. 177 19. Part 6: Cytokines Storms and Their Implications - p. 186 20. Chapter 13. Focusing on the cytokine storm in the battle against COVID-19: the rising role of mesenchymal-derived stem cells - p. 191 21. Chapter 14. Cytokine storm in COVID-19 and other diseases: emerging therapeutic interventions - p. 209 22. Chapter 15. Stem cells as therapeutics and their implications in cytokine storm in COVID-19 - p. 243 23. Part 7: Computational approaches of drug development for COVID-19 and cytokine storm - p. 251 24. Chapter 16. Visualizing chemical functionality and structural insights into SARS-CoV-2 proteins - p. 257 25. Part 8: Stem cells as therapeutics - p. 271 26. Chapter 17. Mesenchymal stromal cells and pleiotropic therapeutic advantages in COVID-19 management - p. 279 27. Chapter 18. Mesenchymal stem cells—role in tuberculosis pathogenesis and persistence - p. 307 28. Part 9: Immunomodulation and Migratory Potential of Stem Cells as Therapeutics - p. 326 29. Chapter 19. Radiosensitivity of cancer stem cells holds promise for the outcome in radiotherapy and COVID-19 infection - p. 337 30. Chapter 20. Immunomodulatory therapeutic potential of mesenchymal stem cells in COVID-19 pathogenesis - p. 343 31. Part 10: Clinical Limitation of Stem Cells Therapy - p. 349 32. Chapter 21. Clinical limitation in stem cells therapy - p. 355 33. Chapter 22. Clinical limitation in stem cell therapy - p. 363 34. Part 11: Stem Cell Based Research and Guidelines - p. 367 35. Chapter 23. Stem cell-based products and the regulatory hurdle race - p. 371 36. Part 12: Stem cell research and socio-scientific community - p. 382 37. Chapter 24. Implications of stem cell therapy on the socio-scientific community - p. 387 38. Appendix A. Conclusion and way forward - p. 395 39. Index - p. 397
Stem Cells: An Alternative Therapy for COVID-19 and Cytokine Storm provides mechanistic insights into the role of stem cells to combat COVID-19 outbreak and other pathologies where cytokines storm is the cause of concern for e.g., radiation exposure, multiple organ failure and sepsis. There has been an increase in number of cases of new diseases in the last decade, including mucormycosis, Zika virus, H1N1 influenza virus, among others. These diseases can be characterized by the induction of cytokine storm, which is mainly responsible for morbidity and mortality.
Stem cell therapy has emerged as a potential treatment for viral diseases, including, but not limited to, COVID-19. Interestingly, clinical trials in patients with COVID-19 complications depicted faster recovery in patients post mesenchymal stem cells therapy owing to the decreased cytokines levels, anti-viral effects and regeneration of the infected tissue.
1. Introduction - p. xxiii 2. Part 1: Outbreak of novel disease - p. xxiv 3. Chapter 1. Targets of SARS-CoV-2: therapeutic implications for COVID-19 - p. 3 4. Part 2: COVID-19 Biology - p. 10 5. Chapter 2. COVID-19 biology: cytokine storms and their implications - p. 17 6. Part 3: SARS-CoV-2 associated complications - p. 25 7. Chapter 3. Comparative clinical investigation of blood profiling in COVID-19 patients - p. 29 8. Chapter 4. SARS-CoV-2-associated complications - p. 45 9. Part 4: Current therapeutics available against SARS-CoV-2 - p. 51 10. Chapter 5. COVID-19 diagnostic approaches and modern mesenchymal stem cell-based treatment - p. 57 11. Chapter 6. Modulation of pentose phosphate pathway augments the efficacy of 2-deoxy-D-glucose in COVID-19 management - p. 69 12. Chapter 7. Therapeutic landscape of SARS-CoV-2 - p. 83 13. Chapter 8. Pharmacotherapeutics for cytokine storm in COVID-19 - p. 101 14. Chapter 9. Clinical investigation of COVID-19 prevention and treatment - p. 127 15. Chapter 10. Potential therapeutic landscape of COVID-19: molecular targets, repurposed drugs, and nano- and cell-based intervention - p. 139 16. Chapter 11. Medical care for SARS-CoV-2 - p. 159 17. Part 5: Opportunistic infections and complications post-COVID-19 - p. 170 18. Chapter 12. Therapeutic approaches for opportunistic infection post-COVID-19 pandemic - p. 177 19. Part 6: Cytokines Storms and Their Implications - p. 186 20. Chapter 13. Focusing on the cytokine storm in the battle against COVID-19: the rising role of mesenchymal-derived stem cells - p. 191 21. Chapter 14. Cytokine storm in COVID-19 and other diseases: emerging therapeutic interventions - p. 209 22. Chapter 15. Stem cells as therapeutics and their implications in cytokine storm in COVID-19 - p. 243 23. Part 7: Computational approaches of drug development for COVID-19 and cytokine storm - p. 251 24. Chapter 16. Visualizing chemical functionality and structural insights into SARS-CoV-2 proteins - p. 257 25. Part 8: Stem cells as therapeutics - p. 271 26. Chapter 17. Mesenchymal stromal cells and pleiotropic therapeutic advantages in COVID-19 management - p. 279 27. Chapter 18. Mesenchymal stem cells—role in tuberculosis pathogenesis and persistence - p. 307 28. Part 9: Immunomodulation and Migratory Potential of Stem Cells as Therapeutics - p. 326 29. Chapter 19. Radiosensitivity of cancer stem cells holds promise for the outcome in radiotherapy and COVID-19 infection - p. 337 30. Chapter 20. Immunomodulatory therapeutic potential of mesenchymal stem cells in COVID-19 pathogenesis - p. 343 31. Part 10: Clinical Limitation of Stem Cells Therapy - p. 349 32. Chapter 21. Clinical limitation in stem cells therapy - p. 355 33. Chapter 22. Clinical limitation in stem cell therapy - p. 363 34. Part 11: Stem Cell Based Research and Guidelines - p. 367 35. Chapter 23. Stem cell-based products and the regulatory hurdle race - p. 371 36. Part 12: Stem cell research and socio-scientific community - p. 382 37. Chapter 24. Implications of stem cell therapy on the socio-scientific community - p. 387 38. Appendix A. Conclusion and way forward - p. 395 39. Index - p. 397
